Jagsonpal Pharmaceuticals Reports 10% Revenue Growth in H1FY26
Filing Summary
Jagsonpal Pharmaceuticals Ltd announced its unaudited financial results for the quarter and half year ended September 30, 2025. The company reported a 10% year-over-year increase in revenue for H1FY26, reaching ₹1,501 million. Profit after tax (PAT) surged by 39% to ₹234 million. Q2FY26 revenue remained stable at ₹745 million. The company maintained a strong cash balance of ₹1,604 million. Key leadership appointments included Amrut Medhekar as Chief Operating Officer and Nirav Vora as Chief Financial Officer. The company continues to focus on operational efficiency and strategic growth.
Jagsonpal Pharmaceuticals Ltd has released its unaudited financial results for the quarter and half year ending September 30, 2025. The company reported a 10% year-over-year increase in revenue for the first half of the fiscal year, amounting to ₹1,501 million. Profit after tax (PAT) for the same period rose by 39% to ₹234 million. For the second quarter, revenue remained stable at ₹745 million, reflecting a slight decrease of 0.3% compared to the previous year.
In terms of financial performance, the company’s Operating EBITDA for H1FY26 was ₹338 million, marking an 8.8% increase from H1FY25. The EBITDA margin for the half year stood at 22.5%. For Q2FY26, the Operating EBITDA was ₹181 million, with a margin of 24.3%. The PAT margin for the second quarter expanded by 154 basis points to 16.9%, while the half-year PAT margin increased by 324 basis points to 15.6%.
Operationally, Jagsonpal Pharmaceuticals maintained its focus on cost management and operational efficiency. The company reported a strong cash balance of ₹1,604 million as of September 30, 2025. This follows a dividend payout of 125%, amounting to ₹166 million. The company also strengthened its leadership team with the appointments of Amrut Medhekar as Chief Operating Officer and Nirav Vora as Chief Financial Officer, both bringing extensive industry experience.
The timeline for the reported financials covers the quarter and half year ending September 30, 2025. The company has highlighted its ongoing efforts to maintain stable revenue amid GST transition adjustments, which have temporarily moderated sales and trade movement.
Jagsonpal Pharmaceuticals operates with a focus on key therapeutic areas including Gynaecology, Orthopaedics, Dermatology, and Child-care. The company has a robust portfolio of drugs and maintains a strong market presence with over 20 brands among the top five in their respective categories. The company is listed on both the National Stock Exchange and the Bombay Stock Exchange.
In the context of market relevance, Jagsonpal Pharmaceuticals continues to build on its legacy of quality and trust, with a strategic focus on sustainable growth and operational excellence. The company has embraced the GST 2.0 reforms, passing on benefits to consumers through reduced prices, aligning with the broader objective of affordable healthcare.
Jagsonpal Pharmaceuticals Ltd is a leading pharmaceutical company with a history of over four decades in the Indian market. The company focuses on developing a diverse portfolio of drugs across various therapeutic segments, maintaining a strong market presence and a commitment to quality and trust.